The Gemfibrozil Study.
In clinical studies in dyslipidaemic patients gemfibrozil has produced falls in LDL and VLDL of 10-20% and 30-50%, respectively, but a rise in HDL of 15-25%. Gemfibrozil also produces increases in both Apo AI and AII, and in kininogen and prekallikrein. Side-effects are not a major problem. The Helsinki Heart Study has compared the effects of gemfibrozil with those of placebo in a group of 4080 dyslipidaemic Finnish men aged 40-55. The results are not yet available but there is reason to believe that the probable level of coronary risk reduction will be at least as great as that reported by the Lipid Research Clinics Study Coronary Primary Prevention Trial (LRC-CPPT).
D000328:Adult; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control*; D005260:Female; D015248:Gemfibrozil; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010421:Pentanoic Acids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014631:Valerates / Q000627:therapeutic use*
D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D010421:Pentanoic Acids; D014631:Valerates; D015248:Gemfibrozil